Financials

	2022	2023
Net sales	54.13M 47.35M 43.67M 40.33M 76.53M 5.16B 77.82M 522M 205M 2.54B 203M 199M 8.74B	80.75M 70.64M 65.15M 60.17M 114M 7.7B 116M 778M 306M 3.79B 303M 297M 13.04B
Net income	-18.11M -15.84M -14.61M -13.49M -25.6M -1.73B -26.03M -175M -68.55M -851M -67.99M -66.51M -2.92B	-20.13M -17.61M -16.24M -15M -28.47M -1.92B -28.94M -194M -76.21M -946M -75.59M -73.94M -3.25B
Net Debt	42.09M 36.82M 33.96M 31.36M 59.51M 4.01B 60.51M 406M 159M 1.98B 158M 155M 6.8B	55.34M 48.41M 44.65M 41.24M 78.25M 5.28B 79.56M 533M 209M 2.6B 208M 203M 8.94B

* Estimated data More financial data

Company Profile

Alimera Sciences, Inc. is a global pharmaceutical company. The Company is focused on helping patients, physicians and partners concerned with retinal health and maintaining better vision longer.

Employees

157

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 23:00:00 13/09/2024 +03			5-day change	1st Jan Change
5.540 ^USD	-0.18%		-.--%	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI

Market Cap	301M 264M 243M 225M 426M 28.74B 433M 2.9B 1.14B 14.16B 1.13B 1.11B 48.66B	P/E 2022	-1.05x	P/E 2023	-5.16x
Enterprise Value	357M 312M 288M 266M 504M 34.01B 513M 3.44B 1.35B 16.76B 1.34B 1.31B 57.6B	EV / Sales 2022	1.13x	EV / Sales 2023	3.49x
Free-Float	94.65%	Yield 2022 *	-	Yield 2023	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI
16/09/24	ANI Pharmaceuticals, Inc. completed the acquisition of Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.	CI
11/09/24	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Looming CPI Data Likely to Provide Rate-Cut Clues	MT
11/09/24	ANI Pharmaceuticals, Alimera Sciences to Close Merger Next Week	MT
10/09/24	Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close	MT
10/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from S&P TMI Index	CI
06/08/24	Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
17/07/24	Processa Pharmaceuticals Appoints Russell Skibsted as CFO	MT
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Comp Value Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Completeness Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 2000 Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 3000E Index	CI

25/06/24	Maxim Downgrades Alimera Sciences to Hold From Buy	MT
25/06/24	Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8	MT
25/06/24	Craig-Hallum Downgrades Alimera Sciences to Hold From Buy, Price Target is $5.50	MT
25/06/24	HC Wainwright Downgrades Alimera Sciences to Neutral From Buy, Price Target is $6	MT
25/03/24	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT

Alimera Sciences, Inc. Stock

Stocks

ALIM

US0162592028

Pharmaceuticals

Valuation: Alimera Sciences, Inc.

Latest news : Alimera Sciences, Inc.

Analysts' recommendations: Alimera Sciences, Inc.

Press Releases: Alimera Sciences, Inc.

News in other languages: Alimera Sciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Alimera Sciences, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Income Statement and Estimates

16/09/24	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences	AQ
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	BU
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	AQ
10/09/24	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences	AQ
10/09/24	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement	BU

Manager	Title	Age	Since
Elliot Maltz DFI	Director of Finance/CFO	41	02/01/2024
Jason Werner COO	Chief Operating Officer	48	02/10/2023
Laura Cegala HRO	Human Resources Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/09/24	Velan Capital Investment Management LP	Issuer sale	Company	14,408,533	26.4940%
16/09/24	Elliot Maltz	Issuer sale	Chief Financial Officer	225,000	0.4137%
16/09/24	David Holland	Issuer sale	Chief Marketing Officer & SVP	1,232,852	2.2669%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALIMERA SCIENCES, INC.	-0.18%	-.--%	-.--%	+75.87%	287M
REGENERON PHARMACEUTICALS, INC.	-0.51%	+1.57%	+17.05%	-7.50%	67.61B
UCB	-5.16%	-8.63%	+38.70%	+202.12%	51.6B
SAMSUNG BIOLOGICS CO.,LTD.	+5.28%	+39.50%	+39.50%	+39.50%	43B
CSL LIMITED	-1.05%	-2.15%	-49.69%	-54.04%	40.94B
BIOGEN INC.	+0.12%	-7.85%	+48.39%	-28.27%	29.4B
MODERNA, INC.	-10.83%	-14.41%	+102.94%	-45.78%	27.09B
INCYTE CORPORATION	-1.53%	-0.13%	+70.16%	+86.29%	23.32B
INNOVENT BIOLOGICS, INC.	-1.11%	-1.82%	+8.35%	+171.71%	19.92B
SWEDISH ORPHAN BIOVITRUM AB	-1.59%	-1.63%	+64.87%	+130.98%	16.91B
Average	-1.64%	-2.87%	+34.03%	+57.09%	32.01B
Weighted average by Cap.	-1.53%	-2.94%	+31.01%	+46.88%

3 years	2.61	5.65
5 years	1.3	9.79
10 years	0	36